1. Academic Validation
  2. Radiation-triggerable bioreactors enable bioenergetic reprograming of cancer stem cell plasticity via targeted arginine metabolism disruption for augmented radio-immunotherapy

Radiation-triggerable bioreactors enable bioenergetic reprograming of cancer stem cell plasticity via targeted arginine metabolism disruption for augmented radio-immunotherapy

  • Biomaterials. 2025 Nov:322:123391. doi: 10.1016/j.biomaterials.2025.123391.
Xuemei Yao 1 Huocheng Yang 1 Sizhe Guo 1 Ying Liu 1 Qiqi Zhang 1 Zao Zhou 1 Menghuan Li 2 Zhong Luo 3
Affiliations

Affiliations

  • 1 School of Life Science, Chongqing University, Chongqing, 400044, China.
  • 2 School of Life Science, Chongqing University, Chongqing, 400044, China. Electronic address: menghuanli@cqu.edu.cn.
  • 3 School of Life Science, Chongqing University, Chongqing, 400044, China. Electronic address: luozhong918@cqu.edu.cn.
Abstract

Cancer Stem Cells (CSCs) are a major cause for the insufficient tumor eradication in the clinic, which universally present enhanced mitochondrial Oxidative Phosphorylation (OXPHOS) to facilitate stemness maintenance and drive treatment resistance. Herein, we report a nanointegrative radiation-triggerable bioreactor (RTB) that selectively remodels CSC-intrinsic arginine metabolism to bioenergetically reprogram CSCs towards a therapeutically-vulnerable differentiated state, leading to durable radio-immunotherapeutic responses in vivo. The RTB nanosystem was developed through the supramolecular integration of radioresponsive iNOS-expressing genetic circuits (pDNAiNOS) and β-lapachone (LAP) into CSC-targeting cationic liposomes. Low-dose radiotherapy (LDR)-induced Nrf2 upregulation readily activates pDNAiNOS to express excessive iNOS, which then depletes CSC-intrinsic arginine while generating abundant nitric oxide (NO) for in-situ amplification of LDR-mediated cytotoxicity. Meanwhile, LDR also upregulates NQO1 expression to promote LAP-mediated ROS generation. These effects could act in a cooperative manner to potently damage CSC mitochondria, which not only blocks OXPHOS activity to drive the differentiation of CSCs for abolishing their self-renewal and resistance capability, but also enhances their propensity towards immunogenic Necroptosis to elicit adaptive antitumor immunity, showing significant potential for treating therapy-persistent tumors.

Keywords

Arginine metabolism disruption; Cancer stem cell therapy; Mitochondrial bioenergetic reprogramming; Necroptosis; Radio-immunotherapy.

Figures
Products
Inhibitors & Agonists
Other Products